RecruitingMature B-Cell NeoplasmNon Hodgkin LymphomaDLBCL

Study of SGR-1505 in Mature B-Cell Neoplasms

Eligible age

18+ yrs

Accepts

All genders

Locations

13 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

Sponsor: Schrödinger, Inc.

You may qualify if…

✓ Subject must have a history of histologically or cytologically confirmed mature B-cell malignancy.
✓ Subject must have measurable or detectable disease according to the applicable disease-specific classification system and meet criteria for initiation of treatment.
✓ Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
✓ Life expectancy ≥ 12 weeks.

You may not qualify if…

✕ The subject is in need of immediate cytoreductive therapy (unless the patient has no remaining treatment choice with potential benefit).
✕ Subject has previous invasive malignancy in the last 2 years.
✕ Subject has a known allergy to SGR-1505 or excipients of SGR-1505.
✕ Subject has symptomatic or active CNS involvement of disease.
✕ Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that would place the participant at increased risk to the use of an investigational drug.